- Home
- SUIG vs CNTB Comparison
SUIG vs CNTB Comparison
Compare SUIG & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SUIG | CNTB |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | United States |
| Employees | 3 | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.4M | 135.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SUIG | CNTB |
|---|---|---|
| Price | $1.18 | $2.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $5.75 | ★ $8.67 |
| AVG Volume (30 Days) | 365.3K | ★ 412.6K |
| Earning Date | 05-07-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | $49.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.08 | $1.23 |
| 52 Week High | $7.25 | $3.82 |
Technical Indicators
Market Signals| Indicator | SUIG | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 39.46 | 59.75 |
| Support Level | $1.10 | $2.30 |
| Resistance Level | $1.54 | $2.68 |
| Average True Range (ATR) | 0.11 | 0.18 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 27.33 | 89.29 |
Price Performance
Historical ComparisonAbout SUIG Sui Group Holdings Limited
Sui Group Holdings Ltd operates a treasury management business. It has established a publicly traded SUI treasury, backed by an exclusive relationship with the Sui Foundation, an independent organization dedicated to the advancement and adoption of the Sui network. The company executes its business by acquiring SUI tokens through open-market purchases, institutional-grade deal flow typically reserved for cryptocurrency funds, and a negotiated purchase agreement with the Sui Foundation. It is focused on capitalizing on technology trends and ecosystem growth relating to SUI, while providing liquid and institutional-grade access to blockchains. The company has one reportable segment, which is a digital asset platform focused on maximizing SUI per share value and advancing the Sui ecosystem.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.